Problem

Drug discovery is an expensive, slow, and failure-prone search through complex biological systems and enormous chemical space. Average pharmaceutical R&D cost is around $2.3 billion per drug, while conventional methods often struggle to predict how a molecule will bind, whether a target has usable pockets, or how a candidate will perform before costly experiments. Isomorphic Labs targets this bottleneck by using AI to improve the probability and speed of finding viable medicines.

The clearest use case is discovering and optimizing drugs against difficult or previously inaccessible targets. Its technology is designed to identify cryptic binding pockets, model novel protein–ligand systems, and rapidly rank molecules by predicted binding affinity, potentially replacing some expensive, time-intensive experimental iteration with faster computational screening.

Product / Service

Isomorphic Labs is building a unified computational drug-design engine, IsoDDE, rather than selling a single disease-specific drug or narrow software tool. The engine uses AI models that operate across multiple therapeutic areas and drug modalities, building on AlphaFold 3’s ability to model molecular structures and interactions. Its models are developed and applied by a cross-disciplinary team spanning machine learning, engineering, medicinal and computational chemistry, and biology.

IsoDDE is used to support both Isomorphic’s wholly owned drug programs and partnered discovery programs with pharmaceutical companies. The platform is intended to predict molecular structures, binding affinities, and novel ligandable pockets, enabling researchers to design, rank, and optimize candidate molecules more quickly. The expected benefit is a more precise and scalable discovery process that can move promising therapeutic programs toward the clinic while reducing reliance on slower, costlier experimental search.

Market

Isomorphic Labs competes in AI-enabled drug discovery and the broader techbio market, alongside companies such as Insitro, Atomwise, XtalPi, Generate Biomedicines, Insilico Medicine, Valo Health, and Biomatter. Its differentiation is the breadth of its unified engine across therapeutic areas and modalities, together with its origins in DeepMind and access to frontier biological AI research such as AlphaFold.

The company has substantial early traction but remains in a pre-commercial or clinical-development phase based on public disclosure. It raised $600 million in its first external round in March 2025 and a further $2.1 billion Series B in May 2026 to scale IsoDDE and advance its pipeline toward the clinic. Partnerships with Novartis, Eli Lilly, and Johnson & Johnson validate pharmaceutical demand, while the company also maintains internal programs; however, named internal drug candidates, sponsored clinical trials, and product revenue have not been publicly disclosed in the available evidence.